{"article_title": "Sanofi's MS Drug Lemtrada Receives Approval in Europe", "article_keywords": ["europe", "saidthe", "lemtrada", "ms", "worldwidethe", "sale", "drug", "parisbased", "genzyme", "regulatory", "takeover", "receives", "sas", "approval", "sanofis", "sanofi"], "article_url": "http://www.wsj.com/articles/SB10001424127887323342404579081291190497728", "article_text": "A multiple-sclerosis drug that was at the center of Sanofi SA's $20 billion takeover battle for Genzyme Corp. three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide.\n\nThe U.S. Food and Drug Administration is expected to decide later this year whether to approve the drug, Paris-based Sanofi said.\n\nThe drug, Lemtrada, was developed by Genzyme, the Cambridge, Mass., biotechnology...", "article_metadata": {"article.template": "snippet", "article.created": "2013-09-17T18:49:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "A multiple-sclerosis drug that was at the center of Sanofi's $20 billion takeover battle for Genzyme three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide.", "creator": "@JeanneWhalen", "image": {"alt": "Sanofi's Lemtrada is the latest of several new drugs to hit the multiple-sclerosis market", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "title": "Sanofi's MS Drug Lemtrada Receives Approval in Europe", "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424127887323342404579081291190497728&headline=Sanofi%26apos%3Bs%20Lemtrada%20is%20the%20latest%20of%20several%20new%20drugs%20to%20hit%20the%20multiple-sclerosis%20market&weburl=http://www.wsj.com/articles/SB10001424127887323342404579081291190497728"}}, "page.site.product": "WSJ", "keywords": "Sanofi,SAN.FR,Biogen%20Idec,BIIB,Teva%20Pharmaceutical%20Industries,TEVA,regulation,government policy,new products,services,research,development,new product approvals,corporate,industrial news,content types,factiva filters,fc&e industry news filter,biotechnology,pharmaceuticals,biopharmaceuticals,drugs,medication,generic drugs", "news_keywords": "Sanofi,SAN.FR,Biogen%20Idec,BIIB,Teva%20Pharmaceutical%20Industries,TEVA,regulation,government policy,new products,services", "article.headline": "Sanofi's Lemtrada is the latest of several new drugs to hit the multiple-sclerosis market", "description": "A multiple-sclerosis drug that was at the center of Sanofi's $20 billion takeover battle for Genzyme three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424127887323342404579081291190497728&headline=Sanofi%26apos%3Bs%20Lemtrada%20is%20the%20latest%20of%20several%20new%20drugs%20to%20hit%20the%20multiple-sclerosis%20market&weburl=http://www.wsj.com/articles/SB10001424127887323342404579081291190497728", "user.type": "nonsubscriber", "article.page": "Business", "page.content.format": "responsive", "article.summary": "A multiple-sclerosis drug that was at the center of Sanofi's $20 billion takeover battle for Genzyme three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide.", "page.site": "wsj", "testkeys": "C", "article.published": "2013-09-17T18:49:00.000Z", "dj.asn": "i-c644", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 1, "word_count": 579, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "A multiple-sclerosis drug that was at the center of Sanofi's $20 billion takeover battle for Genzyme three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide.", "title": "Sanofi's MS Drug Lemtrada Receives Approval in Europe", "url": "http://www.wsj.com/articles/SB10001424127887323342404579081291190497728", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "author": "Jeanne Whalen", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Sanofi\u2019s MS Drug Lemtrada Receives Approval in Europe", "article.type": "Business", "article.id": "SB10001424127887323342404579081291190497728", "user.exp": "default", "article.updated": "2013-09-17T18:49:00.000Z"}, "article_summary": "The U.S. Food and Drug Administration is expected to decide later this year whether to approve the drug, Paris-based Sanofi said.\nA multiple-sclerosis drug that was at the center of Sanofi SA's $20 billion takeover battle for Genzyme Corp. three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide.\nThe drug, Lemtrada, was developed by Genzyme, the Cambridge, Mass., biotechnology..."}